Study to Evaluate the Safety and Efficacy of Oral NRC-2694-A in Combination With Paclitaxel in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma, Who Progressed on or After Immune Checkpoint Inhibitor Therapy
Conditions
Carcinoma · Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Providence Medical Foundation -Fullerton, Fullerton, California, United States
Los Angeles Hematology Oncology Medical Group, Los Angeles, California, United States
Lynn Cancer Center, Boca Raton, Florida, United States
Miami Cancer Center, Miami, Florida, United States
Norton Cancer Institute - Downtown, Louisville, Kentucky, United States
University of Maryland Greenebaum Cancer Center, Baltimore, Maryland, United States
Washington University - Siteman Cancer Center, St Louis, Missouri, United States
Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States
Salib Oncology, Easton, Pennsylvania, United States
University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, United States
Daycare Angels under AOH, Mumbai, Maharashtra, India
Grant Medical Foundation Ruby Hall Clinic, Pune, Maharashtra, India
Basavatarakam Indo American Cancer Hospital & Research Institute, Hyderabad, Telangana, India